We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teleflex Divestitures: What Investors Should Watch in 2026
Read MoreHide Full Article
Key Takeaways
TFX plans to sell Acute Care, Interventional Urology and OEM units for about $2.03B in cash.
OEM close targeted for Q3 2026; FTC second request could delay the other divestiture into H2 2026.
TFX's Q1 2026 margins fell as tariffs and remediation hit; leverage stayed high with $2.51B long-term debt.
Teleflex (TFX - Free Report) is in the middle of a portfolio reset that could reshape both its growth profile and capital allocation priorities. The next several quarters hinge on execution: closing major divestitures, managing transition costs, and delivering cleaner underlying growth in the remaining businesses.
Early 2026 results show demand in key categories, but tariffs and quality remediation costs have pressured margins. With leverage still elevated, the market is likely to stay sensitive to timing and follow-through.
In the past year, shares of Teleflex have gained 5.8% against the industry’s 5.1% decline.
Image Source: Zacks Investment Research
TFX Divestitures Reset the Story
Teleflex plans to sell its Acute Care, Interventional Urology, and original equipment manufacturer (OEM) businesses to two buyers, a move designed to sharpen the company’s focus and increase flexibility to invest in its core markets. Management continues to expect about $2.03 billion of cash proceeds, subject to customary adjustments and approvals.
Timing is the first catalyst investors will track. Teleflex is targeting an OEM close in the third quarter of 2026, while the Acute Care and Interventional Urology transaction is expected to close in the second half of 2026.
Teleflex Timeline Risks Still Drive Volatility
The gating items are clear: regulatory review and the operational demands of separation. The OEM process already cleared an early regulatory milestone when the Hart-Scott-Rodino waiting period expired in March 2026.
The bigger uncertainty sits with Acute Care and Interventional Urology. That transaction received a second request from the U.S. Federal Trade Commission in March 2026, and while Teleflex still expects a second-half 2026 close, review dynamics can create delays or change closing conditions. Any slip extends a period where costs remain elevated and the business operates under added uncertainty.
TFX Capital Plan After Proceeds Arrive
Management has stated intentions to return capital through share repurchases and reduce debt once the proceeds arrive. The sequencing matters because leverage remains meaningful until those dollars are deployed.
Teleflex exited the first quarter of 2026 with $309.4 million in cash and cash equivalents, $103 million of short-term debt, and $2.51 billion of long-term borrowings. Debt-to-capital stood at 45.9% in the first quarter. With that backdrop, interest expense can stay an earnings factor until the divestiture proceeds are applied to deleveraging.
Teleflex Growth Engine Shifts to Vascular
As the portfolio narrows, Teleflex is framing its path around steady mid-single-digit pro forma adjusted constant-currency revenue growth. In the first quarter of 2026, the Vascular segment posted 8.1% reported revenue growth and 4.8% pro forma adjusted constant-currency growth, led by hemostatic products within central venous and other access.
Teleflex highlighted new offerings such as the Arrow VPS Rhythm DLX Device, NaviCurve Stylet, and the Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit, introduced across parts of Europe, the Middle East and Africa.
TFX Interventional Platform Broadens Post Deal
Teleflex’s Interventional business is being reshaped by the BIOTRONIK Vascular Intervention acquisition, which expanded the company’s cath lab footprint and added drug-coated balloons, stents, and balloon catheters. In the first quarter of 2026, Interventional revenues surged 104.4% on a reported basis, but rose 3% on a pro forma adjusted constant-currency basis after adjusting for the acquired business in the prior year.
In the past 30 days, TFX’s 2026 EPS estimates have moved south to $6.70.
Image Source: Zacks Investment Research
TFX Near-Term Scorecard for Investors
Investors should treat 2026 as a milestone year and keep a practical checklist. First, watch divestiture progress: OEM timing toward the third quarter and Acute Care/Interventional Urology progress through regulatory review in the second half. Second, track whether pro forma adjusted constant-currency growth holds in the mid-single-digit range, including Vascular follow-through after a solid first quarter.
Third, monitor margin repair after tariff and remediation impacts. In the first quarter of 2026, adjusted gross margin fell 470 basis points year over year, and gross margin contracted 559 basis points to 56.1%, while adjusted operating margin declined to 6.8%. Fourth, follow the leverage path until proceeds are deployed.
Finally, keep an eye on near-term sentiment signals. Teleflex carries a Zacks Rank #3 (Hold), with Style Scores of VGM: F, Value: C, Growth: F, and Momentum: D. For context, Boston Scientific Corporation (BSX - Free Report) and Medtronic PLC (MDT - Free Report) are among the larger medtech peers investors often compare against when assessing competitive intensity in catheter-based and procedure-driven markets.
View the Zacks #1 Rank List
Image: Bigstock
Teleflex Divestitures: What Investors Should Watch in 2026
Key Takeaways
Teleflex (TFX - Free Report) is in the middle of a portfolio reset that could reshape both its growth profile and capital allocation priorities. The next several quarters hinge on execution: closing major divestitures, managing transition costs, and delivering cleaner underlying growth in the remaining businesses.
Early 2026 results show demand in key categories, but tariffs and quality remediation costs have pressured margins. With leverage still elevated, the market is likely to stay sensitive to timing and follow-through.
In the past year, shares of Teleflex have gained 5.8% against the industry’s 5.1% decline.
Image Source: Zacks Investment Research
TFX Divestitures Reset the Story
Teleflex plans to sell its Acute Care, Interventional Urology, and original equipment manufacturer (OEM) businesses to two buyers, a move designed to sharpen the company’s focus and increase flexibility to invest in its core markets. Management continues to expect about $2.03 billion of cash proceeds, subject to customary adjustments and approvals.
Timing is the first catalyst investors will track. Teleflex is targeting an OEM close in the third quarter of 2026, while the Acute Care and Interventional Urology transaction is expected to close in the second half of 2026.
Teleflex Timeline Risks Still Drive Volatility
The gating items are clear: regulatory review and the operational demands of separation. The OEM process already cleared an early regulatory milestone when the Hart-Scott-Rodino waiting period expired in March 2026.
The bigger uncertainty sits with Acute Care and Interventional Urology. That transaction received a second request from the U.S. Federal Trade Commission in March 2026, and while Teleflex still expects a second-half 2026 close, review dynamics can create delays or change closing conditions. Any slip extends a period where costs remain elevated and the business operates under added uncertainty.
TFX Capital Plan After Proceeds Arrive
Management has stated intentions to return capital through share repurchases and reduce debt once the proceeds arrive. The sequencing matters because leverage remains meaningful until those dollars are deployed.
Teleflex exited the first quarter of 2026 with $309.4 million in cash and cash equivalents, $103 million of short-term debt, and $2.51 billion of long-term borrowings. Debt-to-capital stood at 45.9% in the first quarter. With that backdrop, interest expense can stay an earnings factor until the divestiture proceeds are applied to deleveraging.
Teleflex Growth Engine Shifts to Vascular
As the portfolio narrows, Teleflex is framing its path around steady mid-single-digit pro forma adjusted constant-currency revenue growth. In the first quarter of 2026, the Vascular segment posted 8.1% reported revenue growth and 4.8% pro forma adjusted constant-currency growth, led by hemostatic products within central venous and other access.
Teleflex highlighted new offerings such as the Arrow VPS Rhythm DLX Device, NaviCurve Stylet, and the Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit, introduced across parts of Europe, the Middle East and Africa.
TFX Interventional Platform Broadens Post Deal
Teleflex’s Interventional business is being reshaped by the BIOTRONIK Vascular Intervention acquisition, which expanded the company’s cath lab footprint and added drug-coated balloons, stents, and balloon catheters. In the first quarter of 2026, Interventional revenues surged 104.4% on a reported basis, but rose 3% on a pro forma adjusted constant-currency basis after adjusting for the acquired business in the prior year.
In the past 30 days, TFX’s 2026 EPS estimates have moved south to $6.70.
Image Source: Zacks Investment Research
TFX Near-Term Scorecard for Investors
Investors should treat 2026 as a milestone year and keep a practical checklist. First, watch divestiture progress: OEM timing toward the third quarter and Acute Care/Interventional Urology progress through regulatory review in the second half. Second, track whether pro forma adjusted constant-currency growth holds in the mid-single-digit range, including Vascular follow-through after a solid first quarter.
Third, monitor margin repair after tariff and remediation impacts. In the first quarter of 2026, adjusted gross margin fell 470 basis points year over year, and gross margin contracted 559 basis points to 56.1%, while adjusted operating margin declined to 6.8%. Fourth, follow the leverage path until proceeds are deployed.
Finally, keep an eye on near-term sentiment signals. Teleflex carries a Zacks Rank #3 (Hold), with Style Scores of VGM: F, Value: C, Growth: F, and Momentum: D. For context, Boston Scientific Corporation (BSX - Free Report) and Medtronic PLC (MDT - Free Report) are among the larger medtech peers investors often compare against when assessing competitive intensity in catheter-based and procedure-driven markets.
You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.